Baylor St. Luke's Medical Center is the private adult teaching hospital of Baylor College of Medicine jointly owned with CHI St. Luke's Health. The medical staff at the hospital includes full-time Baylor faculty, as well as community physicians.

During the past decade, St. Luke's Episcopal Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 26 clinical trials were completed, i.e. on average, 288.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 12 clinical trials were completed. i.e. 1200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's Episcopal Hospital" #1 sponsor was "Abbott Medical Devices" with 9 trials, followed by "Boston Scientific Corporation" with 8 trials sponsored, "Gilead Sciences" with 6 trials sponsored, "M.D. Anderson Cancer Center" with 4 trials sponsored and "National Cancer Institute (NCI)" with 4 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's Episcopal Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Northwestern University" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "CHI St. Luke's Health, Texas" with 1 trials as a collaborator and "Dr. Naga Chalasani, MD, Indiana University" with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's Episcopal Hospital" are "Coronary Artery Disease" (10 trials), "Atherosclerosis" (3 trials), "Carotid Artery Disease" (3 trials), "Carotid Stenosis" (3 trials) and "Coronary Disease" (3 trials). Many other conditions were trialed in "St. Luke's Episcopal Hospital" in a lesser frequency.

Most popular intervention types in "St. Luke's Episcopal Hospital" are "Device" (32 trials), "Drug" (23 trials), "Biological" (9 trials), "Other" (6 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Bevacizumab" (2 trials), "Cisplatin" (2 trials), "Laboratory Biomarker Analysis" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's Episcopal Hospital" are 59 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "St. Luke's Episcopal Hospital". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in St. Luke's Episcopal Hospital, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's Episcopal Hospital, 3 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 14 trials that are defined as “Not Applicable".

St. Luke's Episcopal Hospital has several departments that took part in Clinical trials: "St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital" - 15 trials